Twist Bioscience Corporation (TWST) is a biotechnology company operating in the synthetic biology industry. Its primary business activities involve the design, synthesis, and manufacturing of synthetic DNA, RNA, and proteins for various applications, spanning healthcare, food and agriculture, industrial chemicals, and academic research. The company generates revenue through its synthetic biology and next-generation sequencing (NGS) tools product lines, as well as biopharma services for antibody discovery, optimization, and development. Twist Bioscience's...
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | TMO | Thermo Fisher Scientific Inc. | 216.83 Bn | 33.00 | 4.96 | 35.68 Bn |
| 2 | DHR | Danaher Corp /De/ | 162.47 Bn | 46.38 | 6.69 | 16.86 Bn |
| 3 | IDXX | Idexx Laboratories Inc /De | 56.88 Bn | 55.36 | 13.65 | 1.09 Bn |
| 4 | A | Agilent Technologies, Inc. | 39.82 Bn | 32.64 | 5.87 | 3.41 Bn |
| 5 | IQV | Iqvia Holdings Inc. | 38.85 Bn | 30.28 | 2.44 | 15.19 Bn |
| 6 | NTRA | Natera, Inc. | 31.32 Bn | -101.29 | 14.80 | 0.18 Bn |
| 7 | MTD | Mettler Toledo International Inc/ | 28.99 Bn | 34.68 | 7.35 | 2.21 Bn |
| 8 | WAT | Waters Corp /De/ | 22.92 Bn | 35.32 | 7.38 | 1.49 Bn |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| EV to Assets | 2.71 | 2.69 | |
| EV to Cash from Ops. | -36.53 | 18.14 | |
| EV to Debt | 19.21 | 52.51 | |
| EV to EBIT | -22.61 | 19.22 | |
| EV to EBITDA | -15.61 | 4.35 | |
| EV to Free Cash Flow [EV/FCF] | -23.00 | 2.84 | |
| EV to Market Cap | 0.94 | 1.52 | |
| EV to Revenue | 4.62 | 4.79 | |
| Price to Book Value [P/B] | 3.91 | 1.34 | |
| Price to Earnings [P/E] | -23.79 | 22.02 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| Dividend Coverage Ratio | 0.00 | -1.96 | |
| Dividend Payout Ratio % | 0.00 | 2.83 | |
| Dividend per Basic Share | 0.00 | 0.19 | |
| FCF Dividend Payout Ratio % | 0.00 | 1.92 | |
| Interest Coverage | 0.00 | -126.58 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| Capex Growth (1y) % | -451.69 | -31.50 | |
| Cash and Equivalents Growth (1y) % | -19.12 | 21.37 | |
| Dividend Growth (1y) % | 0.00 | 0.24 | |
| EBIAT Growth (1y) % | 62.79 | -55.24 | |
| EBITDA Growth (1y) % | 40.88 | -447.96 | |
| EBIT Growth (1y) % | 63.03 | -40.50 | |
| EBT Growth (1y) % | 63.03 | -70.94 | |
| EPS Growth (1y) % | 63.89 | -70.02 | |
| FCF Growth (1y) % | -9.34 | 56.33 | |
| Gross Profit Growth (1y) % | 43.23 | 185.11 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| Asset Utilization Ratio | 0.59 | 0.56 | |
| Cash Payout Ratio | 0.00 | 0.01 | |
| Cash Ratio | 2.00 | 1.21 | |
| Current Ratio | 3.64 | 2.64 | |
| Debt to Equity Ratio | 0.19 | -0.80 | |
| Interest Cover Ratio | 0.00 | -126.58 | |
| Times Interest Earned | 0.00 | -126.58 |
| Metric | Value | Industry | Percentile |
|---|---|---|---|
| EBITDA Margin % | -13.80 | -129.91 | |
| EBIT Margin % | -20.43 | -156.71 | |
| EBT Margin % | -20.43 | -162.23 | |
| Gross Margin % | 50.70 | 47.70 | |
| Net Profit Margin % | -20.60 | -189.30 |